300 North Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

300 North Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-37,941	Closed	-$1.44M	–	102
2015 Q1	$1.44M	Buy	37,941 +181	+0.5%	+$6.22K	0.32%	92
2014 Q4	$1.07M	Buy	37,760 +65	+0.2%	+$1.81K	0.25%	89
2014 Q3	$954K	Hold	37,695	–	–	0.25%	94
2014 Q2	$1.1M	Hold	37,695	–	–	0.27%	82
2014 Q1	$975K	Buy	+37,695	New	+$1.01M	0.25%	82

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

300 North Capital's PTLA Position: Q2 2015 in Review

300 North Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2015, closing a stake of 37,941 shares — an estimated $1.44M sold.

300 North Capital first reported a position in PTLA in Q1 2014 and held it in 5 quarters. The position peaked at $1.44M in Q1 2015. 160 funds tracked by Wall St. Rank hold PTLA as of Q2 2015.

300 North Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
300 North Capital sold 37,941 Portola Pharmaceuticals, Inc. shares in Q2 2015, an estimated $1.44M.
300 North Capital first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 5 quarters.
300 North Capital's Portola Pharmaceuticals, Inc. position peaked at $1.44M in Q1 2015.
160 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.